Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.
作者信息
Kimmich Christoph R, Terzer Tobias, Benner Axel, Hansen Timon, Carpinteiro Alexander, Dittrich Tobias, Veelken Kaya, Jauch Anna, Huhn Stefanie, Basset Marco, Goldschmidt Hartmut, Müller-Tidow Carsten, Schönland Stefan O, Hegenbart Ute
机构信息
Division of Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany.
出版信息
Am J Hematol. 2021 Jul 1;96(7):E253-E257. doi: 10.1002/ajh.26191. Epub 2021 May 3.
PMID:33844864
Abstract
摘要
Zotero 插件